ACAD
Acadia Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
ACAD fundamentals
Acadia Pharmaceuticals (ACAD) released its earnings on Feb 25, 2026: revenue was 283.99M (YoY +9.39%), missed estimates; EPS was 1.6 (YoY +86.05%), beat estimates.
Revenue / YoY
283.99M
+9.39%
EPS / YoY
1.6
+86.05%
Report date
Feb 25, 2026
ACAD Earnings Call Summary for Q4,2025
- Revenue Milestone: FY25 adjusted revenue surpasses $1 billion for first time at $1.08 billion (14% YoY growth).
- NUPLAZID Growth: Q4 net sales $189 million (17% YoY); 2026 guidance $760-790 million (10-14% growth).
- DAYBUE Expansion: Q4 sales $110 million (13% YoY); 2026 STIX-driven growth to $460-490 million.
- Pipeline Momentum: Remlifanserin Phase II ADP readout expected Q3 2026; ACP-271 first-in-human study begins Q1 2026.
- Financial Strength: FY26 total revenue guidance $1.22-1.28 billion; $250 million one-time tax benefit.
EPS
Actual | -0.57 | -0.27 | -0.54 | -0.42 | -0.42 | -0.27 | -0.09 | -0.27 | -0.7 | -0.21 | -0.17 | -0.26 | -0.27 | 0.01 | -0.4 | 0.28 | 0.1 | 0.2 | 0.2 | 0.86 | 0.11 | 0.16 | 0.42 | 1.6 | |||||||||||
Forecast | -0.4783 | -0.4392 | -0.3835 | -0.4736 | -0.5299 | -0.3045 | -0.2595 | -0.2376 | -0.6179 | -0.2478 | -0.1942 | -0.2471 | -0.2145 | -0.0978 | -0.4477 | 0.2889 | 0.0488 | 0.1777 | 0.1381 | 0.2157 | 0.0867 | 0.1381 | 0.1729 | 0.137 | |||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -19.17% | +38.52% | -40.81% | +11.32% | +20.74% | +11.33% | +65.32% | -13.64% | -13.29% | +15.25% | +12.46% | -5.22% | -25.87% | +110.22% | +10.65% | -3.08% | +104.92% | +12.55% | +44.82% | +298.70% | +26.87% | +15.86% | +142.91% | +1067.88% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 90.07M | 110.10M | 120.58M | 121.01M | 106.55M | 115.22M | 131.61M | 130.76M | 115.47M | 134.56M | 130.71M | 136.49M | 118.46M | 165.24M | 211.70M | 231.04M | 205.83M | 241.96M | 250.40M | 259.60M | 244.32M | 264.57M | 278.63M | 283.99M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 90.75M | 103.41M | 118.82M | 122.76M | 112.01M | 124.90M | 127.93M | 135.39M | 121.91M | 130.41M | 138.76M | 134.23M | 120.06M | 166.18M | 192.32M | 223.79M | 208.31M | 235.95M | 248.83M | 255.61M | 238.77M | 262.02M | 276.54M | 292.79M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -0.75% | +6.47% | +1.48% | -1.43% | -4.87% | -7.75% | +2.88% | -3.42% | -5.29% | +3.19% | -5.80% | +1.68% | -1.33% | -0.57% | +10.08% | +3.24% | -1.19% | +2.55% | +0.63% | +1.56% | +2.32% | +0.97% | +0.76% | -3.00% |
Earnings Call
You can ask Aime
What does Acadia Pharmaceuticals do and what are its main business segments?Did Acadia Pharmaceuticals beat or miss consensus estimates last quarter?What is the market's earnings forecast for Acadia Pharmaceuticals next quarter?What is the revenue and EPS growth rate for Acadia Pharmaceuticals year over year?What factors drove the changes in Acadia Pharmaceuticals's revenue and profit?What were the key takeaways from Acadia Pharmaceuticals's earnings call?What is Acadia Pharmaceuticals's latest dividend and current dividend yield?What is Acadia Pharmaceuticals's gross profit margin?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
